
## **INTERLEUKIN 17-A (IL-17A) IN PSORIASIS**

A MESSENGER PROTEIN (OR CYTOKINE) FOUND TO PLAY A KEY ROLE IN PSORIASIS AND OTHER AUTOIMMUNE DISEASES<sup>1</sup>

## HOW INCREASED LEVELS OF IL-17A AFFECT THE SKIN IN PSORIASIS<sup>2,3</sup>

Too many skin cells cause:



## **IL-17A: A NEW POTENTIAL TARGET**

Newer, innovative treatments have been developed in response to this unmet need. These treatments specifically target the cytokines that trigger inflammation, such as IL-17A interrupt the inflammatory cycle in psoriasis. They have shown positive results in the treatment and management of psoriasis<sup>4</sup>.

 1. Kirkham BW, Kavanaugh A, Reich K, Immunology, 2014; 141:133-142.
 GLDEIM/AIN457A/0311a

 2. Onishi RM, Gaffen SL, Immunology, 2010; 129: 311-21.
 GLDEIM/AIN457A/0311a

 3. Nestle FQ, Kaplan DH, Barker J. N Engl J Med 2009; 351(5):496-509.
 GLDEIM/AIN457A/0311a

 4. National Psoniasis Foundation. Psoniatic disease: about psoniasis. Accessed February 2016.
 GLDEIM/AIN457A/0311a

 5. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. J Am Acad Dermatol 1999; 41(3 Pt 1):401-7
 GLDEIM/AIN457A/0311a

 6. National Psoniasis Foundation. The immune system and psoniatic disease. Accessed February 2016.
 GLDEIM/AIN457A/0311a

 7. Kopf M, Bachmann MF, Marsland BJ. Nat Rev Drug Discov. 2010; 9(9):703-18.
 GLDEIM/AIN457A/0311a

